Humanized Anti-TWEAK Antibody Framework Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions associated with TWEAK, such as inflammatory and neuronal disorders, face challenges due to the immunogenic response elicited by non-human antibodies, leading to reduced efficacy and potential allergic reactions.
Innovation Solution
Development of anti-TWEAK antibodies with specific heavy and light chain variable domain sequences that are at least 95% identical to certain amino acid sequences, forming antigen binding sites that bind to human TWEAK, minimizing immunogenic responses and designed to be effectively human, reducing the risk of neutralizing antibody responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-human antibodies are used to treat TWEAK-related conditions, then therapeutic efficacy is achieved, but immunogenic responses and allergic reactions occur
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of the antibody to achieve at least 95% identity between the antibody framework regions and human germline sequences. This sequence parameter modification reduces immunogenicity while maintaining therapeutic efficacy against TWEAK, directly resolving the contradiction between effectiveness and safety.
Solution Approach 2:
The patent uses copying by creating humanized antibodies that replicate human antibody frameworks with minimal differences. The antibody is designed to closely copy human immunoglobulin sequences in the framework regions while retaining the necessary binding specificity for TWEAK, thereby reducing immunogenic response.
2Object-affected harmful factors
If humanized antibodies are developed to reduce immunogenicity, then safety is improved, but manufacturing complexity increases
Solution Approach 1:
The patent specifies precise parameter changes requiring at least 95% identity in framework regions between the antibody and human germline sequences. This quantifiable parameter provides clear design criteria that simplify the complex task of humanized antibody development by establishing measurable targets for sequence alignment.
Solution Approach 2:
The patent segments the antibody into distinct functional regions: framework regions that must match human sequences (95% identity) and complementarity determining regions (CDRs) that provide TWEAK binding specificity. This segmentation allows independent optimization of each region, simplifying the overall design process.
Data Source
AI summary
Anti-Tweak antibodies are described.